Irritable Bowel Syndrome (IBS) - Market Insights, Epidemiology and Market Forecast-2028

Warm Autoimmune Hemolytic Anemia (wAIHA ) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of WAIHA in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Warm Autoimmune Hemolytic Anemia (wAIHA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
Study Period: 2017-2028
Warm Autoimmune Hemolytic Anemia (wAIHA) - Disease Understanding and Treatment Algorithm
The DelveInsight Warm Autoimmune Hemolytic Anemia (wAIHA) market report gives the thorough understanding of the Warm Autoimmune Hemolytic Anemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Warm Autoimmune Hemolytic Anemia in the US, Europe, and Japan.
Warm Autoimmune Hemolytic Anemia Epidemiology
The Warm Autoimmune Hemolytic Anemia (wAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of AIHA, total prevalent cases of wAIHA, type-specific prevalent cases, prevalent cases based on gender) scenario of Warm Autoimmune Hemolytic Anemia (wAIHA ) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, the total number of prevalent cases of Warm Autoimmune Hemolytic Anemia (wAIHA) in 7 MM was found to be 82,807, in the year 2017.
?
Warm Autoimmune Hemolytic Anemia Drug Chapters
This segment of the Warm Autoimmune Hemolytic Anemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market forecast solely focuses on the market revenue generated by the pharmacological treatment (inclusive of corticosteroids as the first line of therapy, second line of therapy includes : splenectomy, Rituximab, immunosuppressive drugs such as Cyclosporin A whereas Alemtuzumab and hematopoietic stem cell transplantation (HSCT) are considered as the options of last resort.. Detailed chapter for upcoming therapies like Fostamatinib (Rigel Pharmaceuticals) and APL-2 (Apellis Pharmaceuticals, Inc.) have been covered in the report.
Warm Autoimmune Hemolytic Anemia Market Outlook
The Warm Autoimmune Hemolytic Anemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Warm Autoimmune Hemolytic Anemia in 7MM was found to be USD 280.0 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.
Warm Autoimmune Hemolytic Anemia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
?
Warm Autoimmune Hemolytic Anemia Report Insights
Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Warm Autoimmune Hemolytic Anemia Report Key Strengths
10 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Warm Autoimmune Hemolytic Anemia Report Assessment
Current Treatment Practices
Unmet Needs
Detailed Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Benefits
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Warm Autoimmune Hemolytic Anemia market
Organize sales and marketing efforts by identifying the best opportunities for Warm Autoimmune Hemolytic Anemia market
To understand the future market competition in the Warm Autoimmune Hemolytic Anemia market.

List Of Tables

Table 1: Classification of wAIHA
Table 2: Prevalent Patient Population of wAIHA in 7MM (2017-2028)
Table 3: Total Prevalent Cases of AIHA in the United States (2017-2028)
Table 4: Prevalence of wAIHA in the United States (2017-2028)
Table 5: Type-specific Prevalence of wAIHA in the United States (2017-2028)
Table 6: Gender-specific Prevalence of wAIHA in the United States (2017-2028)
Table 7: Total Prevalent Cases of AIHA in Germany (2017-2028)
Table 8: Prevalence of wAIHA in Germany (2017-2028)
Table 9: Type-specific Prevalence of wAIHA in Germany (2017-2028)
Table 10: Gender-specific Prevalence of wAIHA in Germany (2017-2028)
Table 11: Total Prevalent Cases of AIHA in France (2017-2028)
Table 12: Prevalence of wAIHA in France (2017-2028)
Table 13: Type-specific Prevalence of wAIHA in France (2017-2028)
Table 14: Gender-specific Prevalence of wAIHA in France (2017-2028)
Table 15: Total Prevalent Cases of AIHA in Italy (2017-2028)
Table 16: Prevalence of wAIHA in Italy (2017-2028)
Table 17: Type-specific Prevalence of wAIHA in Italy (2017-2028)
Table 18: Gender-specific Prevalence of wAIHA in Italy (2017-2028)
Table 19: Total Prevalent Cases of AIHA in Spain (2017-2028)
Table 20: Prevalence of wAIHA in Spain (2017-2028)
Table 21: Type-specific Prevalence of wAIHA in Spain (2017-2028)
Table 22: Gender-specific Prevalence of wAIHA in Spain (2017-2028)
Table 23: Total Prevalent Cases of AIHA in the UK (2017-2028)
Table 24: Prevalence of wAIHA in the UK (2017-2028)
Table 25: Type-specific Prevalence of wAIHA in the UK (2017-2028)
Table 26: Gender-specific Prevalence of wAIHA in the UK (2017-2028)
Table 27: Total Prevalent Cases of AIHA in Japan (2017-2028)
Table 28: Prevalence of wAIHA in Japan (2017-2028)
Table 29: Type-specific Prevalence of wAIHA in Japan (2017-2028)
Table 30: Gender-specific Prevalence of wAIHA in Japan (2017-2028)
Table 31: Treatment Flow
Table 32: Fostamatinib, Clinical Trial Description, 2019
Table 33: APL-2, Clinical Trial Description, 2019
Table 34: SYNT001, Clinical Trial Description, 2019
Table 35: BIV009, Clinical Trial Description, 2019
Table 36: 7 Major Market Size of wAIHA in USD Million (2017-2028)
Table 37: United States Market Size of wAIHA in USD Million (2017-2028)
Table 38: The US Market Size of wAIHA by LoT in USD Million (2017-2028)
Table 39: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Table 40: Germany Market Size of wAIHA in USD Million (2017-2028)
Table 41: Germany Market Size of wAIHA by LoT in USD Million (2017-2028)
Table 42: Germany Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Table 43: France Market Size of wAIHA in USD Million (2017-2028)
Table 44: France Market Size of wAIHA by LoT in USD Million (2017-2028)
Table 45: France Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Table 46: Italy Market Size of wAIHA in USD Million (2017-2028)
Table 47: Italy Market Size of wAIHA by LoT in USD Million (2017-2028)
Table 48: Italy Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Table 49: Spain Market Size of wAIHA in USD Million (2017-2028)
Table 50: Spain Market Size of wAIHA by LoT in USD Million (2017-2028)
Table 51: Spain Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Table 52: The United Kingdom Market Size of wAIHA in USD Million (2017-2028)
Table 53: The UK Market Size of wAIHA by LoT in USD Million (2017-2028)
Table 54: The UK Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Table 55: Japan Market Size of wAIHA in USD Million (2017-2028)
Table 56: Japan Market Size of wAIHA by LoT in USD Million (2017-2028)
Table 57: Japan Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

List Of Figures

Figure 1: Mechanisms of antibody-sensitized RBC destruction in w-AIHA
Figure 2: Prevalent Patient Population of wAIHA in 7MM (2017-2028)
Figure 3: Total Prevalent Cases of AIHA in the United States (2017-2028)
Figure 4: Prevalence of wAIHA in the United States (2017-2028)
Figure 5: Type-specific Prevalence of wAIHA in the United States (2017-2028)
Figure 6: Gender-specific Prevalence of wAIHA in the United States (2017-2028)
Figure 7: Total Prevalent Cases of AIHA in Germany (2017-2028)
Figure 8: Prevalence of wAIHA in Germany (2017-2028)
Figure 9: Type-specific Prevalence of wAIHA in Germany (2017-2028)
Figure 10: Gender-specific Prevalence of wAIHA in Germany (2017-2028)
Figure 11: Total Prevalent Cases of AIHA in France (2017-2028)
Figure 12: Prevalence of wAIHA in France (2017-2028)
Figure 13: Type-specific Prevalence of wAIHA in France (2017-2028)
Figure 14: Gender-specific Prevalence of wAIHA in France (2017-2028)
Figure 15: Total Prevalent Cases of AIHA in Italy (2017-2028)
Figure 16: Prevalence of wAIHA in Italy (2017-2028)
Figure 17: Type-specific Prevalence of wAIHA in Italy (2017-2028)
Figure 18: Gender-specific Prevalence of wAIHA in Italy (2017-2028)
Figure 19: Total Prevalent Cases of AIHA in Spain (2017-2028)
Figure 20: Prevalence of wAIHA in Spain (2017-2028)
Figure 21: Type-specific Prevalence of wAIHA in Spain (2017-2028)
Figure 22: Gender-specific Prevalence of wAIHA in Spain (2017-2028)
Figure 23: Total Prevalent Cases of AIHA in the UK (2017-2028)
Figure 24: Prevalence of wAIHA in the UK (2017-2028)
Figure 25: Type-specific Prevalence of wAIHA in the UK (2017-2028)
Figure 26: Gender-specific Prevalence of wAIHA in the UK (2017-2028)
Figure 27: Total Prevalent Cases of AIHA in Japan (2017-2028)
Figure 28: Prevalence of wAIHA in Japan (2017-2028)
Figure 29: Type-specific Prevalence of wAIHA in Japan (2017-2028)
Figure 30: Gender-specific Prevalence of wAIHA in Japan (2017-2028)
Figure 31: Treatment algorithm for warm AIHA in adults
Figure 32: Unmet Needs of wAIHA
Figure 33: 7 Major Market Size of wAIHA in USD Million (2017-2028)
Figure 34: Market Size of wAIHA in the United States, USD Million (2017-2028)
Figure 35: The US Market Size of wAIHA by LoT in USD Million (2017-2028)
Figure 36: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Figure 37: Market Size of wAIHA in Germany, USD Million (2017-2028)
Figure 38: Germany Market Size of wAIHA by LoT in USD Million (2017-2028)
Figure 39: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Figure 40: Market Size of wAIHA in France USD Million (2017-2028)
Figure 41: France Market Size of wAIHA by LoT in USD Million (2017-2028)
Figure 42: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Figure 43: Market Size of wAIHA in Italy, USD Million (2017-2028)
Figure 44: Italy Market Size of wAIHA by LoT in USD Million (2017-2028)
Figure 45: Italy Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Figure 46: Market Size of wAIHA in Spain, USD Million (2017-2028)
Figure 47: Spain Market Size of wAIHA by LoT in USD Million (2017-2028)
Figure 48: Spain Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Figure 49: Market Size of wAIHA in the United Kingdom, USD Million (2017-2028)
Figure 50: The UK Market Size of wAIHA by LoT in USD Million (2017-2028)
Figure 51: The UK Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Figure 52: Market Size of wAIHA in Japan, USD Million (2017-2028)
Figure 53: Japan Market Size of wAIHA by Therapies in USD Million (2017-2028)
Figure 54: Japan Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)
Figure 55: Market Drivers
Figure 56: Market Barriers

Irritable Bowel Syndrome - Pipeline Review, H2 2019

Irritable Bowel Syndrome - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2019, provides an overview of the Irritable Bowel Syndrome

USD 2000 View Report

Irritable Bowel Syndrome (IBS) - Market Insights, Epidemiology and Market Forecast-2028

Warm Autoimmune Hemolytic Anemia (wAIHA ) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market

USD 6250 View Report

Short Bowel Syndrome - Pipeline Review, H2 2019

Short Bowel Syndrome - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H2 2019, provides an overview of the Short Bowel Syndrome

USD 2000 View Report

Irritable Bowel Syndrome - Pipeline Review, H2 2019

Irritable Bowel Syndrome - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2019, provides an overview of the Irritable Bowel Syndrome

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available